NAION
14 articles on NAION, researched and written by the Shotlee Editorial Team from primary sources.
Ozempic Face and Hair Loss: Evidence for GLP-1 Drug Side Effects
Weight-loss medications like Wegovy and Mounjaro have surged in popularity, leading to increased discussions about their side effects. This article delves into the scientific evidence for frequently reported concerns such as 'Ozempic face,' hair thinning, digestive problems, and eye conditions associated with GLP-1 agonists.
11 min read
Beyond Ozempic: The Peptide Revolution in Health
Discover how natural peptides are challenging the pharmaceutical industry, offering a new paradigm for healing, metabolic health, and cognitive enhancement amidst evolving regulatory landscapes.
10 min read
GLP-1 Drugs and Vision Loss: Understanding NAION Lawsuits
Recent lawsuits are raising serious questions about the potential for GLP-1 medications, widely used for diabetes and weight loss, to cause a rare but devastating eye condition known as NAION, leading to permanent vision loss. This article delves into the allegations, scientific evidence, and ongoing legal proceedings.
6 min read
Semaglutide NAION Risk: New Study Findings for Weight Loss Patients
A recent analysis published in JAMA Ophthalmology reveals a significant increase in NAION risk associated with semaglutide compared to SGLT2 inhibitors, though absolute risk remains low.
8 min read
Study: Semaglutide Does Not Raise NAION Risk in Obesity, Diabetes
A large study presented in San Diego reveals semaglutide use is not associated with higher risk of non-arteritic anterior ischemic optic neuropathy (NAION) in patients with overweight or obesity. In fact, it lowered NAION risk by 64% among those with type 2 diabetes compared to non-GLP-1 therapies. Experts emphasize continued monitoring of blood sugar and blood pressure.
5 min read
Ozempic Users Warned: Don't Skip Exercise, Study Urges
Ozempic users who skip exercise face suboptimal results, according to a new study in Sports Medicine on GLP-1 drugs like Victoza and Saxenda. Among 193 adults, those combining medication with structured workouts saw the best outcomes, while sedentary users fared worst. Meanwhile, one patient's rare blindness side effect highlights ongoing risks.
5 min read
Study Finds Gastrointestinal Issues Top GLP-1 Side Effects
A comprehensive review of over 1,700 clinical trials reveals gastrointestinal adverse events as the most consistent side effects of GLP-1 medications like Ozempic and Wegovy. While these drugs show potential protective effects against infections and dementia, lawsuits over stomach paralysis and vision loss are mounting. Understand the findings and what they mean for your treatment.
5 min read
Why US Patients Sue Ozempic Makers Over Gastroparesis, Vision Loss
Lawsuits against Ozempic manufacturer Novo Nordisk are exploding in the US, with patients alleging the company hid severe side effects like gastroparesis and sudden vision loss from semaglutide. Originally a type 2 diabetes drug, Ozempic's popularity as a weight loss shot has sparked debates on safety and marketing. Despite high demand, experts urge medical supervision to avoid serious risks.
5 min read
Study: Wegovy Vision Loss Risk 5x Higher Than Ozempic
A groundbreaking study reveals Wegovy carries a fivefold higher risk of vision-threatening ischemic optic neuropathy compared to Ozempic. Analyzing millions of FDA reports, researchers link the risk to semaglutide's higher doses in Wegovy. Amid rising lawsuits, patients need to weigh benefits against potential eye health dangers.
5 min read
Study: Ozempic, Wegovy NAION Risk Twofold Higher vs. SGLT2i Drugs
New research from Veterans' Affairs shows Ozempic and Wegovy users face double the risk of NAION—a serious vision loss condition—compared to SGLT2i drugs. Published in JAMA Ophthalmology, the study urges doctors to warn patients about potential permanent blindness from semaglutide-based GLP-1 medications. As lawsuits mount, understand the implications for diabetes and weight management.
5 min read
GLP-1 Kidney Risks: Study Compares Ozempic to SGLT2 Drugs
A recent Danish study in JAMA Internal Medicine highlights higher kidney risks with popular GLP-1 drugs like Ozempic compared to SGLT2 inhibitors. While GLP-1s offer weight loss benefits, understanding these findings is crucial for patients. Learn the science, risks, and how to protect your kidneys.
5 min read
GLP-1 Side Effects & Lawsuits: What Users Must Know
GLP-1 medications like Ozempic and Wegovy have transformed weight management, but rising lawsuits highlight serious side effects like gastroparesis and vision loss. This guide breaks down the science, risks, and strategies for safe use. Learn how to monitor symptoms and integrate lifestyle changes effectively.
4 min read
Ozempic Weight Loss Boom: Rising Legal Risks
Semaglutide-based Ozempic has become a weight loss sensation beyond diabetes treatment. Yet, over 1,800 US lawsuits signal serious risks including gastroparesis, bowel issues, and vision loss from NAION. UK and Irish prescribers face growing negligence exposure.
2 min read
Unseen Effects: Potential Impacts of GLP-1 Weight Loss Medications
GLP-1 medications, while effective for weight loss, can have various side effects. Understanding these potential impacts is crucial for informed decision-making and patient care. These medications affect different parts of the body, leading to diverse reactions based on individual physiology.
7 min read